VivoSeq
Nephrology

Renal Allograft Recipients

5

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Renal Allograft Recipients is an early-stage landscape with 5 programs across 6 companies. The most active players are Bristol-Myers Squibb, Novartis, Veloxis Pharmaceuticals. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3Novartis logo

Novartis

2 programs

Phase 3V

Veloxis Pharmaceuticals

1 program

Phase 3Roche logo

Roche

1 program

Phase 3Pfizer logo

Pfizer

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSProtein / enzyme120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Unknown status3 · 20%
Terminated1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT04877288·102 enrolled
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
Completed·Pfizer logoPfizer·Phase 3·NCT00273871·190 enrolled
Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients
Completed·Pfizer logoPfizer·Phase 2·NCT00518271·120 enrolled
Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
Completed·Pfizer logoPfizer·Phase 4·NCT00261820·160 enrolled
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
Completed·NNorthwestern University·Phase 4·NCT00866879·275 enrolled
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
Completed·Sanofi logoSanofi·Phase 2·NCT00235300·240 enrolled
Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids
Completed·Pfizer logoPfizer·Phase 4·NCT01601821·245 enrolled
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
Completed·SSeoul National University Hospital·Phase 3·NCT01055964·80 enrolled
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Completed·LLower Saxony Center for Nephrology·Phase 4·NCT00373165·150 enrolled
Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients
Completed·Novartis logoNovartis·Phase 3·NCT00228020·212 enrolled
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00307125·757 enrolled
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
Terminated·WWashington University School of Medicine·N/A·NCT00235781·90 enrolled
Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients
Unknown status·SSeoul St. Mary's Hospital·Phase 4·NCT02036554·234 enrolled
TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)
Unknown status·UUniversity Hospital Schleswig-Holstein·Phase 1·NCT00223093·10 enrolled
Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes
Unknown status·UUniversity Hospital Schleswig-Holstein·Phase 1·NCT00223067·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)